These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32951510)

  • 1. The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease.
    Breeze P; Thomas C; Thokala P; Lafortune L; Brayne C; Brennan A
    Med Decis Making; 2020 Oct; 40(7):912-923. PubMed ID: 32951510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
    Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
    BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future cost-effectiveness and equity of the NHS Health Check cardiovascular disease prevention programme: Microsimulation modelling using data from Liverpool, UK.
    Kypridemos C; Collins B; McHale P; Bromley H; Parvulescu P; Capewell S; O'Flaherty M
    PLoS Med; 2018 May; 15(5):e1002573. PubMed ID: 29813056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
    Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
    Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation.
    Thomas C; Brennan A; Goka E; Squires HY; Brenner G; Bagguley D; Buckley Woods H; Gillett M; Leaviss J; Clowes M; Heathcote L; Cooper K; Breeze P
    BMJ Open; 2020 Sep; 10(9):e037486. PubMed ID: 32912949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Eddy DM; Schlessinger L; Kahn R
    Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of the US Food and Drug Administration Added Sugar Labeling Policy for Improving Diet and Health.
    Huang Y; Kypridemos C; Liu J; Lee Y; Pearson-Stuttard J; Collins B; Bandosz P; Capewell S; Whitsel L; Wilde P; Mozaffarian D; O'Flaherty M; Micha R;
    Circulation; 2019 Jun; 139(23):2613-2624. PubMed ID: 30982338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and recommendations for the health-economic evaluation of primary prevention programmes for dementia.
    Handels R; Wimo A
    Aging Ment Health; 2019 Jan; 23(1):53-59. PubMed ID: 29039976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study.
    Lee Y; Mozaffarian D; Sy S; Huang Y; Liu J; Wilde PE; Abrahams-Gessel S; Jardim TSV; Gaziano TA; Micha R
    PLoS Med; 2019 Mar; 16(3):e1002761. PubMed ID: 30889188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
    Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P
    Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial.
    Pollard DJ; Brennan A; Dixon S; Waugh N; Elliott J; Heller S; Lee E; Campbell M; Basarir H; White D;
    BMJ Open; 2018 Apr; 8(4):e016766. PubMed ID: 29627802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.
    Herman WH; Edelstein SL; Ratner RE; Montez MG; Ackermann RT; Orchard TJ; Foulkes MA; Zhang P; Saudek CD; Brown MB;
    Am J Manag Care; 2013; 19(3):194-202. PubMed ID: 23544761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What will the cardiovascular disease slowdown cost? Modelling the impact of CVD trends on dementia, disability, and economic costs in England and Wales from 2020-2029.
    Collins B; Bandosz P; Guzman-Castillo M; Pearson-Stuttard J; Stoye G; McCauley J; Ahmadi-Abhari S; Araghi M; Shipley MJ; Capewell S; French E; Brunner EJ; O'Flaherty M
    PLoS One; 2022; 17(6):e0268766. PubMed ID: 35767575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis.
    Breeze PR; Thomas C; Squires H; Brennan A; Greaves C; Diggle PJ; Brunner E; Tabak A; Preston L; Chilcott J
    Diabet Med; 2017 May; 34(5):632-640. PubMed ID: 28075544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.